Bulky disease is an adverse prognostic factor in patients treated with chemotherapy comprised of cyclophosphamide, doxorubicin, vincristine, and prednisone with or without radiotherapy for aggressive lymphoma

Richard B. Wilder, Maria A. Rodriguez, Chul S Ha, Barbara Pro, Mark A. Hess, Fernando Cabanillas, James D. Cox

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

BACKGROUND. In the current study, the authors analyzed prognostic factors in patients with aggressive lymphoma treated with a chemotherapy regimen comprised of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) with or without radiotherapy. METHODS. Between September 1988 and December 1996, 294 patients with newly diagnosed, clinical Ann Arbor Stage I-IV, aggressive lymphoma were enrolled on 2 protocols at The University of Texas M. D. Anderson Cancer Center. Patients on these studies had a relatively favorable prognosis; 100% had M. D. Anderson tumor scores ≤ 2 and 95%% had International Prognostic Indices (IPIs) ≤ 2. Treatment was comprised of 5 ± 1 (mean ± the standard deviation) cycles of CHOP chemotherapy with or without involved-field radiotherapy to a total dose of 40.1 ± 3.3 grays (mean ± the standard deviation). RESULTS. The median length of follow-up was 61 months. Three factors were found to retain independent prognostic significance on multivariate analysis in terms of progression-free survival: > 1 extranodal site of disease (P < 0.001), bulky disease (≥ 7 cm) (P = 0.005), and an at least 10% elevation in the serum lactate dehydrogenase (LDH) level (P = 0.007). Patient age > 60 years (P = 0.001), bulky disease (P = 0.016), and an at least 10% elevation in the serum LDH level (P = 0.040) also were found to be independent prognostic factors for overall survival. CONCLUSIONS. The independent prognostic factors in the current study suggest that either the M. D. Anderson tumor score system or the IPI can be used to select which aggressive lymphoma patients are at high risk for disease recurrence based on their having more than two adverse factors and who consequently are candidates for more intensive frontline therapy. Involved-field radiotherapy should be considered in those patients with bulky lymphomas.

Original languageEnglish (US)
Pages (from-to)2440-2446
Number of pages7
JournalCancer
Volume91
Issue number12
DOIs
StatePublished - Jun 15 2001
Externally publishedYes

Fingerprint

Vincristine
Prednisone
Doxorubicin
Cyclophosphamide
Lymphoma
Radiotherapy
Drug Therapy
Neoplasms
Disease-Free Survival
Multivariate Analysis
Recurrence
Survival
Therapeutics
Serum

Keywords

  • Aggressive lymphomas
  • Bulky disease
  • Cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy
  • Prognostic factors
  • Serum lactate dehydrogenase (LDH)

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Bulky disease is an adverse prognostic factor in patients treated with chemotherapy comprised of cyclophosphamide, doxorubicin, vincristine, and prednisone with or without radiotherapy for aggressive lymphoma. / Wilder, Richard B.; Rodriguez, Maria A.; Ha, Chul S; Pro, Barbara; Hess, Mark A.; Cabanillas, Fernando; Cox, James D.

In: Cancer, Vol. 91, No. 12, 15.06.2001, p. 2440-2446.

Research output: Contribution to journalArticle

Wilder, Richard B. ; Rodriguez, Maria A. ; Ha, Chul S ; Pro, Barbara ; Hess, Mark A. ; Cabanillas, Fernando ; Cox, James D. / Bulky disease is an adverse prognostic factor in patients treated with chemotherapy comprised of cyclophosphamide, doxorubicin, vincristine, and prednisone with or without radiotherapy for aggressive lymphoma. In: Cancer. 2001 ; Vol. 91, No. 12. pp. 2440-2446.
@article{05e0e797bd9041de9344c8dc20cf7df2,
title = "Bulky disease is an adverse prognostic factor in patients treated with chemotherapy comprised of cyclophosphamide, doxorubicin, vincristine, and prednisone with or without radiotherapy for aggressive lymphoma",
abstract = "BACKGROUND. In the current study, the authors analyzed prognostic factors in patients with aggressive lymphoma treated with a chemotherapy regimen comprised of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) with or without radiotherapy. METHODS. Between September 1988 and December 1996, 294 patients with newly diagnosed, clinical Ann Arbor Stage I-IV, aggressive lymphoma were enrolled on 2 protocols at The University of Texas M. D. Anderson Cancer Center. Patients on these studies had a relatively favorable prognosis; 100{\%} had M. D. Anderson tumor scores ≤ 2 and 95{\%}{\%} had International Prognostic Indices (IPIs) ≤ 2. Treatment was comprised of 5 ± 1 (mean ± the standard deviation) cycles of CHOP chemotherapy with or without involved-field radiotherapy to a total dose of 40.1 ± 3.3 grays (mean ± the standard deviation). RESULTS. The median length of follow-up was 61 months. Three factors were found to retain independent prognostic significance on multivariate analysis in terms of progression-free survival: > 1 extranodal site of disease (P < 0.001), bulky disease (≥ 7 cm) (P = 0.005), and an at least 10{\%} elevation in the serum lactate dehydrogenase (LDH) level (P = 0.007). Patient age > 60 years (P = 0.001), bulky disease (P = 0.016), and an at least 10{\%} elevation in the serum LDH level (P = 0.040) also were found to be independent prognostic factors for overall survival. CONCLUSIONS. The independent prognostic factors in the current study suggest that either the M. D. Anderson tumor score system or the IPI can be used to select which aggressive lymphoma patients are at high risk for disease recurrence based on their having more than two adverse factors and who consequently are candidates for more intensive frontline therapy. Involved-field radiotherapy should be considered in those patients with bulky lymphomas.",
keywords = "Aggressive lymphomas, Bulky disease, Cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy, Prognostic factors, Serum lactate dehydrogenase (LDH)",
author = "Wilder, {Richard B.} and Rodriguez, {Maria A.} and Ha, {Chul S} and Barbara Pro and Hess, {Mark A.} and Fernando Cabanillas and Cox, {James D.}",
year = "2001",
month = "6",
day = "15",
doi = "10.1002/1097-0142(20010615)91:12<2440::AID-CNCR1279>3.0.CO;2-2",
language = "English (US)",
volume = "91",
pages = "2440--2446",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "12",

}

TY - JOUR

T1 - Bulky disease is an adverse prognostic factor in patients treated with chemotherapy comprised of cyclophosphamide, doxorubicin, vincristine, and prednisone with or without radiotherapy for aggressive lymphoma

AU - Wilder, Richard B.

AU - Rodriguez, Maria A.

AU - Ha, Chul S

AU - Pro, Barbara

AU - Hess, Mark A.

AU - Cabanillas, Fernando

AU - Cox, James D.

PY - 2001/6/15

Y1 - 2001/6/15

N2 - BACKGROUND. In the current study, the authors analyzed prognostic factors in patients with aggressive lymphoma treated with a chemotherapy regimen comprised of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) with or without radiotherapy. METHODS. Between September 1988 and December 1996, 294 patients with newly diagnosed, clinical Ann Arbor Stage I-IV, aggressive lymphoma were enrolled on 2 protocols at The University of Texas M. D. Anderson Cancer Center. Patients on these studies had a relatively favorable prognosis; 100% had M. D. Anderson tumor scores ≤ 2 and 95%% had International Prognostic Indices (IPIs) ≤ 2. Treatment was comprised of 5 ± 1 (mean ± the standard deviation) cycles of CHOP chemotherapy with or without involved-field radiotherapy to a total dose of 40.1 ± 3.3 grays (mean ± the standard deviation). RESULTS. The median length of follow-up was 61 months. Three factors were found to retain independent prognostic significance on multivariate analysis in terms of progression-free survival: > 1 extranodal site of disease (P < 0.001), bulky disease (≥ 7 cm) (P = 0.005), and an at least 10% elevation in the serum lactate dehydrogenase (LDH) level (P = 0.007). Patient age > 60 years (P = 0.001), bulky disease (P = 0.016), and an at least 10% elevation in the serum LDH level (P = 0.040) also were found to be independent prognostic factors for overall survival. CONCLUSIONS. The independent prognostic factors in the current study suggest that either the M. D. Anderson tumor score system or the IPI can be used to select which aggressive lymphoma patients are at high risk for disease recurrence based on their having more than two adverse factors and who consequently are candidates for more intensive frontline therapy. Involved-field radiotherapy should be considered in those patients with bulky lymphomas.

AB - BACKGROUND. In the current study, the authors analyzed prognostic factors in patients with aggressive lymphoma treated with a chemotherapy regimen comprised of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) with or without radiotherapy. METHODS. Between September 1988 and December 1996, 294 patients with newly diagnosed, clinical Ann Arbor Stage I-IV, aggressive lymphoma were enrolled on 2 protocols at The University of Texas M. D. Anderson Cancer Center. Patients on these studies had a relatively favorable prognosis; 100% had M. D. Anderson tumor scores ≤ 2 and 95%% had International Prognostic Indices (IPIs) ≤ 2. Treatment was comprised of 5 ± 1 (mean ± the standard deviation) cycles of CHOP chemotherapy with or without involved-field radiotherapy to a total dose of 40.1 ± 3.3 grays (mean ± the standard deviation). RESULTS. The median length of follow-up was 61 months. Three factors were found to retain independent prognostic significance on multivariate analysis in terms of progression-free survival: > 1 extranodal site of disease (P < 0.001), bulky disease (≥ 7 cm) (P = 0.005), and an at least 10% elevation in the serum lactate dehydrogenase (LDH) level (P = 0.007). Patient age > 60 years (P = 0.001), bulky disease (P = 0.016), and an at least 10% elevation in the serum LDH level (P = 0.040) also were found to be independent prognostic factors for overall survival. CONCLUSIONS. The independent prognostic factors in the current study suggest that either the M. D. Anderson tumor score system or the IPI can be used to select which aggressive lymphoma patients are at high risk for disease recurrence based on their having more than two adverse factors and who consequently are candidates for more intensive frontline therapy. Involved-field radiotherapy should be considered in those patients with bulky lymphomas.

KW - Aggressive lymphomas

KW - Bulky disease

KW - Cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy

KW - Prognostic factors

KW - Serum lactate dehydrogenase (LDH)

UR - http://www.scopus.com/inward/record.url?scp=0035876093&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035876093&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(20010615)91:12<2440::AID-CNCR1279>3.0.CO;2-2

DO - 10.1002/1097-0142(20010615)91:12<2440::AID-CNCR1279>3.0.CO;2-2

M3 - Article

C2 - 11413536

AN - SCOPUS:0035876093

VL - 91

SP - 2440

EP - 2446

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 12

ER -